Trial Profile

A first in human study of BHV 1600 for treatment of Dilated cardiomyopathy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV-1600 (Primary)
Indications Dilated cardiomyopathy
Focus First in man; Therapeutic Use

Most Recent Events

03 Mar 2025 According to Biohaven Therapeutics media release, this study is expected to be completed in 1H 2025.
16 Dec 2024 Status changed from planning to recruiting, According to the Biohaven Therapeutics Media Release.
16 Dec 2024 According to the Biohaven Therapeutics Media Release, company initiated dosing in this study with BHV-1600 in 4Q 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com